Contineum Therapeutics, Inc. Income Statement
CTNM|1 years of annual SEC 10-K data (FY2024-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
Contineum Therapeutics, Inc. reported $0 in revenue and $42M in net loss for FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.08 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 |
|---|---|
| Revenue | $0 |
| SG&A Expense | $12.5M |
| R&D Expense | $38.4M |
| Operating Income | -$50.9M |
| Income Tax | $0 |
| Net Income | -$42.3M |
| EPS (Basic) | $1.36 |
| EPS (Diluted) | $0.08 |
| Shares Outstanding | 3.4M |